Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ
@APassaroMD
Followers
6,517
Following
226
Media
959
Statuses
6,507
lung cancer oncologist & researcher @IEOufficiale
Milan, Italy
Joined December 2016
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Bolivia
• 682741 Tweets
Golpe de Estado
• 336701 Tweets
Georgia
• 238172 Tweets
Starmer
• 205784 Tweets
Luis Arce
• 178420 Tweets
Ejército
• 170822 Tweets
Knicks
• 168104 Tweets
La Paz
• 130944 Tweets
Sunak
• 129522 Tweets
Çekya
• 120822 Tweets
#BizimÇocuklar
• 117756 Tweets
#BBCDebate
• 99500 Tweets
Cenk
• 98027 Tweets
Kayla
• 89682 Tweets
Evo Morales
• 84709 Tweets
Barış Alper
• 84694 Tweets
Arda
• 80964 Tweets
#CZEvTUR
• 71149 Tweets
Juan José Zúñiga
• 69807 Tweets
Plaza Murillo
• 64062 Tweets
Hakan
• 59704 Tweets
#TURvÇEK
• 56835 Tweets
América Latina
• 55467 Tweets
Son 16
• 48085 Tweets
Slovakia
• 39745 Tweets
Mert
• 39563 Tweets
Kenan
• 39408 Tweets
Montella
• 33263 Tweets
Kerem
• 32809 Tweets
Jess
• 32702 Tweets
Forvet
• 31414 Tweets
Maçın
• 29930 Tweets
#GEOPOR
• 29785 Tweets
İsmail
• 28568 Tweets
Ferdi
• 28221 Tweets
Harriet
• 27262 Tweets
António Silva
• 26160 Tweets
Hakem
• 24770 Tweets
Avusturya
• 24098 Tweets
Semih
• 24087 Tweets
Mikautadze
• 20944 Tweets
Bill Cobbs
• 14318 Tweets
Ciaran
• 13933 Tweets
Pinned Tweet
That you are here - that life exists and identity,
That the powerful play goes on, and you may contribute a verse.
Walt Whitman, Leaves of Grass (1892)
3
5
46
🔥📡 kaboooom!
Amazing news at
@AACR
#Targets21
🎯KRAS G12D is therapeutic TARGET!
@Mirati
presented the structure of MRTX1133, the reversible KRAS
#G12D
inhibitor.
Great news for
#LCSM
,
#Pancreatic
Cancer
#CRC
, and more 🙌🙌🙌
5
110
302
The light is On💡
Out our
@NEJM
editorial on Trastuzumab Deruxtecan in HER2-Mutant NSCLC by Bob Li et al.
#LCSM
#LungCancer
@peters_solange
11
56
230
💡🔥Out today, the Oncogene-addicted metastatic NSCLC ESMO Guideline. A significant effort to improve the management of patients w/
#lungcancer
harbouring 🔟 different gene alterations! This is an amazing manuscript & I am glad to be a part of it
#LCSM
2
79
232
🆕🌟I’m very proud to share our last manuscript titled “ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell
#LungCancer
”
#LCSM
A global effort to improve the management of EGFR-positive disease
Thanks to all the authors!!!
3
48
221
Happy to share our latest
#review
on overcoming therapy resistance in EGFR-mutant, just published with
@NatureCancer
💡
5
71
219
💥
#ASCO22
#LCSM
Concomitant publication
@NEJM
for the KRAYSTAL-1 ph2 trial, just presented by
@AlexSpiraMDPhD
Another step forward for the KRAS-g12C mutant NSCLC…& much more is coming!
0
60
191
#ASCO21
we are ready to go!💨
Here, some of the most interesting abstract on
#LungCancer
#LCSM
that will be presented, very soon!
Take a look at that & enjoy 👁🗨
1
75
175
💥🔥just out in
@Annals_Oncology
, the NEW
@myESMO
guideline for non-oncogene addicted metastatic NSCLC
#LCSM
‼️
Honoured to be part of this important document (waiting for oncogene addicted one), lead by
@HendriksLizza
&
@MartinReck2
4
59
167
#ESMO19
#LCSM
Do you want to know how to treat patients with NSCLC and predictive biomarkers?
Here, an excellent vademecum exploring available and upcoming target agents for
#lungcancer
by
@dplanchard
2
91
161
👁🗨
#ESMO20
the day after🔈
#LungCancer
take-home 📬
▪️KN024:31.9% 5yr-OS w/ 1L IO
▪️CROWN:PFS-HR Lorlatinib 0.28.🆕standard?Maybe no!
▪️LungART:PORT for pN2 cannot be reccomended as SoC
▪️ADAURA: towards approval
▪️Sotirasib for KRAS G12C ORR 32.3%/DoR 10.9m
▪️BLU-945:👈🏻😉
#LCSM
6
76
157
🚀 Excited to announce our latest
@CellCellPress
publication on "Cancer biomarkers: Emerging trends and clinical implications for personalized treatment."
An important collaboration shedding light on promising avenues in cancer research.📑✨
5
54
156
#ASCO22
will be a powerful year of transition for
#LungCancer
track.
Here, my selection of key-5 oral abstracts, waiting for the full presentations & discussion
#LCSM
👁🗨keep an eye to t poster sessions😉
3
63
148
🛎 just published in
@NEJM
our editorial on the groundbreaking ALINA trial, evaluating the role of adjuvant alectinib in patients with resected NSCLC carrying ALK rearrangements.
A major advance for our patients!
🔗
0
30
151
#ESMO23
Presidential 1
THE LungCancer story ♥️
- PAPILLON ✅
- ALINA ✅
- LIBRETTO 431 ✅
- CheckMate77L ✅
What else?! 🔥
3
25
142
I’m honoured to be appointed as Chair of the new
@myESMO
Communication Committee‼️
I look forward to continuing our work, started in the last two years in the Press Committee, with the talented ESMO staff & all the new committee members!
20
8
140
🆕🌟NOW out, our systematic review on Uncommon
#EGFR
Compound mutations in NSCLC , with a comprehensive evaluation on prevalence, distribution, clinical performance with difference TKIs & testing molecular techniques
#LCSM
#LungCancer
#MedTwitter
4
55
135
🆕
@NatureCancer
🔥
Identified 6 distinct
#lungcancer
proteome subtypes w/ striking differences in immune cell composition & subtype-spec expression of immune checkpoints suggesting potential clinical value for tailored treatm stratification
#LCSM
👏Amazing
2
44
130
📍Excellent slide by S.Gadgeel at
@IASLC
#WCLC21
, summarising the agents (TKIs & mAb) under investigation for the treat of
#lungcancer
harbouring
#EGFR
Exon20 insertions (Ex20ins)
#LCSM
At present time,
#Amivantamab
(
@US_FDA
approved) &
#Moborcetinib
are one step ahead!
0
55
129
🚨
#ESMO20
is ready to go!
Here my Top5️⃣
#LungCancer
abstracts
#LCSM
3 abstract in presidential session and many other with very interesting data.
I can't wait to see the presentations & full data!
What do you think about?
👉Suggestions, ideas, comments?
6
52
128
🧿Just out in
@JCO_ASCO
our review on ADCs in
#LungCancer
focusing on recent advances & implementing strategies, including structure-based drug design, mechanism of action, and concepts of resistance
@peters_solange
🔗
#LCSM
4
31
123
A must-read for all the stakeholders, to understand why
#COVID19
is a confirmed
#healthcare
emergency!
Please read this piece of remarkable value just published on Lancet, focusing on the dramatic Italian status with a careful data analysis
#OncoAlert
2
55
122
🌟 Proud to be part of the special issue focused on “Thoracic
#Oncology
: Current & Future Therapy”just out on
@JCO_ASCO
, w/ a review discussing the resistance to ICIs with focus on novel strategies
@JulieBrahmer
Scott Antonia,
@TonyMok9
&
@peters_solange
#LCSM
2
27
115
🚨
#WCLC20
#LungCancer
Here,my Top5️⃣ abstracts
#LCSM
1️⃣Sotorasib in KRAS G12C:ready for the action🌟
2️⃣Neoadjuvant Atezo:hoping in another brick in the wall🧱
3️⃣
#immunotherapy
in relapsed
#mesothelioma
?
4️⃣KN-589:does combo beats mono in PDL1>50%?
5️⃣ITACA:tailoring adjuvant chemo
2
30
108
In our editorial, pub in
@NEJM
we summarized all the results of several phase 2 trials in HER2-mutant
#lungcancer
Diff TKIs failed; trastuzumab & T-DM1 showed some signals, while T-DXd confirmed a significant improvement in ORR, PFS & OS
#LCSM
1
23
107
A new era of
#SocialMedia
in
#Healthcare
is started!
Thanks to the
@JCO_ASCO
@ASCO
, now the
@Twitter
account can appear in the corresponding author details!
Fantastic!!
4
34
103
#ASCO23
#LCSM
- KEYNOTE-671
@HwakeleeMD
𝗡𝗲𝗼𝗮𝗱𝗷 𝗽𝗹𝘂𝘀 𝗮𝗱𝗷 𝗣𝗲𝗺𝗯𝗿𝗼 𝗶𝗻 𝗲𝗮𝗿𝗹𝘆 𝗡𝗦𝗖𝗟𝗖
Primary endpoint: EFS & OS
With a mFU of 25.2m
EFS at 24m: 62.4% vs 40.6% (HR 0.58)
Estimated 24m OS rate: 80.9 vs 77.6%
pCR 18.1 vs 4.0%
MPR 30.2 vs 11.0%
The
@NEJM
0
44
105
In EGFR+
#lungcancer
treated w/
#Osimertinib
, histo transformation & other off-target alterations r frequent early emerging resistance mechanisms & r associated w/ poor outcomes
An interesting paper just published
@CCR_AACR
by
@AdamJSchoenfeld
et al
#LCSM
1
40
104
🔥
#LCSM
💥
@Nature
CLIP1-LTK is a new therapeutic target in
#lungcancer
NO more words: THANKS… to all the researchers and colleagues that made this possible!
👉
1
26
101
🛎 Just published on
@JTOonline
our review discussing t recent advances on t role of
#EGFR
TKIs in NSCLC w/ UNCOMMON, non-exon 20 ins, EGFR mut’s
A very hot topic in t EGFR field
Thanks to all t coauthors
@peters_solange
@DrSanjayPopat
#LCSM
#LungCancer
2
45
100
👁️🗨️🆕 in
@JAMAOnc
our review
𝗔𝗱𝗷𝘂𝘃𝗮𝗻𝘁 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗥𝗲𝘀𝗲𝗰𝘁𝗲𝗱 𝗡𝗦𝗖𝗟𝗖 𝗛𝗮𝗿𝗯𝗼𝗿𝗶𝗻𝗴 𝗘𝗚𝗙𝗥 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝘀
In this article, we thoroughly reviewed & discussed the key findings from clinical trials that assess the efficacy of EGFR
0
36
100
BL-B01D1 the first bispecific antibody-drug conjugate targeting EGFR & HER3
Here, the focus in pretreated EGFR mutant NSCLC. An excellent perspective
#ASCO23
0
32
98
☄️
#PressRelease
The combination of Osimertinib plus chemo showed a strong PFS improvement vs Osi alone for patients with EGFR-mutated advanced lung cancer in FLAURA2 Ph III trial
#LCSM
📌2023 will be an historical year for EGFR+ management: stay tuned 🔊
2
29
100
#ASCO24
is ready to start soon! Here, my top🔟 selection with explanation, among the
#LungCancer
abstracts
#LCSM
🧵
5
38
99
#ELCC23
was simply great!
▪️2571 participants in total
▪️1732 on-site in Copenaghen🇩🇰
▪️431 abstract submitted
▪️8 Proferred Papers
▪️13 Mini Orals
▪️201 Posters
🔹7 DailyReporter article
Congrats to
@MartinReck2
&
@NReguart
!
4
12
97
It is for me a great honour to be appointed as new Chair of
@myESMO
Press & Media Affairs Committee!
Thank you so much to the ESMO President
@peters_solange
& to all the executive board, for believing in me.
I'll try to do my best!
7
10
93
📍🔨 Antibody-drug conjugates (ADCs) under development in
#lungcancer
?
Here a very comprehensive table of ADCs combo presented by
@cbcbc1971
during the
@IALSC
#WCLC21
#LCSM
1
35
91
#ASCO20
#LCSM
Simply amazing looking through the updated OS analysis of ALEX trials presented by
@peters_solange
Impressive: to date, median OS not yet reached for Alectinib (HR 0.67 vs Crizo 57.6m)
5-yr survival 62.5% vs 45.5%, of course in favour of Alectinib
That’s it!
3
30
92
🚨PressRelease by
@JanssenGlobal
The combo of amivantamab plus p-based chemo (w/ or w/out Lazertinib) vs chemo alone achieved a statistically significant & clinically meaningful improvement in PFS in NSCLC with EGFR mut’s after Osimertinib
0
36
90
#ASCO20
#LCSM
💥Registrational dataset for pralsetinib (BLU-667), in RET fusion positive NSCLC.
96% tumore reduction, regardless prior treatment or not !
🔹durable responses
🔹good safety profile
🔹CNS penetrant
Do you need anything else?
@FDAOncology
we are waiting for you!
3
36
88
🛎 Just out in
@Annals_Oncology
a crucial update of
@myESMO
Early & loc adv NSCLC Clinical Guidelines by
@JordiRemon
et al.
Integrated very important recommendations on adjuvant Osimertinib & updated indication for PORT in early setting
#LCSM
1
39
88
#COVID19
In Italy in the last two days 902 deaths related to COVID19
Too sad these data to add any other words
I pray for all the victims and their families. Very close to all my colleagues who are at war
#staystrong
2
13
89
🫂ESMO is my society!
**We confirm our solidarity and unconditioned support to all oncology professionals and cancer patients, with NO geographic boundaries**
4
21
87
🦋Today, the robust clinical development of Amivantamab for EGFR-mutant NSCLC adds a new chapter looking towards a stronger future.
Soon, the Paloma-3 study will be discussed by Natasha Leighl.
Honored to have been part of this significant milestone
#ASCO24
1
24
88
🆕
@CD_AACR
Functional STK11 mutations is associated with resistance to ICIs in
#lungcancer
& is reversed by STAT3 knockdown 🌟
#LCSM
1
33
85
#ESMO20
#LCSM
💥💥💥
1/3 of
#LungCancer
pts with high PDL1 treated with Pembrolizumab alive @ 5️⃣ years
0
17
86
#ELCC22
Targeting
#KRAS
G12C is one the major achievement in
#lungcancer
history.
Here an excellent summary slide by
@peters_solange
.
👁🗨Improving the understanding of primary/acquired resistance & the role of co-mutations is the key for the future therapeutic steps
#LCSM
2
25
81
🛎 Just out, the analysis of updated database of 1023 cases harbouring uncommon EGFR mutations.
Honoured to contribute to this important effort to improve the understanding of these rare biological & clinical entity!
#LCSM
4
25
83
🔐
#COVID19
#vaccination
in pts with
#cancer
Here, all the available & essential resources, just released in the last days
📌
@myESMO
📌
@ASCO
📌
@AACR
📌
@sitcancer
@US_FDA
2
43
83
💫What not to miss during
#ESMO22
?
Of course, the presentation by
@CharlesSwanton
on air pollution and NSCLC!! An important topic with a significant role for cancer prevention
#LCSM
(Presidential 1)
1
19
80
#ESMO22
is ready to start!🔥
▪️1,913 abstracts
▪️76 LBA
This year’s tagline "Understanding the disease to provide better CARE for
#cancer
patients"
We are working hard to improve your Congress experience with
#DailyReporter
coverage!
Stay tuned🗞💡
1
16
80
Out in
@NatureComms
analysis of acquired resistance mechanisms to Osi in pts with EGFR-mut NSCLC from the AURA3 trial
EGFR muts & MET amp occurred in 22% and 18% of pts, respectively.
HER2 amp, MAPK/PI3K and fusions (FGFR3-TACC3, NTRK1-TMP3, RET-ERC1,
1
24
82
⚠️ Crucial slide presented by
@Tony_Calles
#ASCO20
discussing the role of ICIs in
#LungCancer
harbouring driven mutation.
Pay attention in clinical practice, to the increased rate of irAEs w/ the sequence of ICI followed by TKI.
#LCSM
#OncoAlert
#EdBook
2
37
82
A must-read manuscript just out on
@Cancer_Cell
identifying 3 different subtypes of
#lungcancer
fibroblasts that define distinct functional subtypes & potential therapeutic paradigms
#LCSM
1
28
81
Fascinating
@CCR_AACR
paper on intratumoral
#immunotherapy
for early-stage solid tumors.
615 clinical trials utilizing neoadjuvant intratumoral immunotherapy are ongoing.
#Cancer
#Oncology
#Oncoalert
Congrats to
@BenWestphalen
and co-authors
4
26
81
🆕Another must-read manuscript about
#COVID19
emergency in Italy.
Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy - Early Experience and Forecast During an Emergency Response
@JAMANetworkOpen
#OncoAlert
2
54
77
🆕✨in
@NatureComms
, in the path of ADAURA. Identified 3 diff predictive genomic signatures to potentially stratify resected EGFR+ NSCLC pts w/ distinct adj outcomes & providing guidance towards future personalized adj target therapy.
#LCSM
#LCAM
1
34
78
Amivantamab plus Lazertinib to overcome osimertinib resistance in EGFR+
#lungcancer
#ASCO21
#LCSM
💡👁🗨Very interesting signal for a specific
#clinicaltrial
: in IHC+ for EGF/MET(combined EGFR+MET H score>400) ORR 90%; mDoR 9.7m, mPFS 12.5m (n = 20)
1
31
77
Out in
@NatureMedicine
an interesting and comprehensive perspective by
@DrRoyHerbstYale
discussing the impact of personalized treatment approaches for non-small-cell lungcancer & the future of
#PrecisionMedicine
#LCSM
#LCAM
2
24
69
#ELCC22
Tony Mok summary slide on Exon20 insertions in
#lungcancer
Exciting times with two specific approved drugs for the pretreated setting: amivantamab (FDA/EMA) & moborcetinib (FDA)
That’s it! 📌
#LCSM
0
31
69
🛎
#ESMO22
#LCSM
discussion by S. Delaloge
@GustaveRoussy
on air pollution &
#lungcancer
@myESMO
PM2.5 as air pollutants as promoter of lung cancer in non smokers !!!
2
24
71
🛎🛎
Do not miss this important reading!
@myESMO
statements for
#COVID19
#vaccination
in patients with
#cancer
A robust and structured evaluation need for all the stakeholders in the
#oncology
field
4
36
70
🆕 just published on
@ESMO_Open
#Cancer
care during the spread of
#COVID19
in Italy
Our joint work by
@matteolambe
& Italian friends
Please, read it and share with us your comments and ideas
#OncoAlert
0
35
71
🚨Waiting for OS ADAURA during
#ASCO23
, just out in
@JAMAOnc
our review discussing Adjuvant Treatments for Resected NSCLC Harboring EGFR mutations, discussing current evidence and future perspective
👁️🗨️
@JAMANetwork
@EGFRResisters
1
26
72
Fewer
#cancer
diagnoses during
#COVID19
epidemic due to unprecedented pressure on
#healthcare
services. Here,the Netherlands perspective
@theLancetOncol
showing a decrease in cancer diagnoses when compared w/ the period before the pandemic
#OncoAlert
5
51
70
1
29
70
#ESMO22
#LCSM
@DrSanjayPopat
discussing ADAURA updates using Osi in adjuvant setting:
The trajectory is different according to the stage, opening the scenario of potential diff duration of response: are we following the trajectory of hormon+ high-risk resected breast cancer?
2
20
69
🛎👁🗨 The CheckMate 9LA is just out on
@TheLancetOncol
👉🏻Here,our Comment discussing this new treatment option (Nivo + Ipi + 2c of P-based chemo)for the 1L of mNSCLC (Sq & non-Sq) (
@EMA_News
&
@US_FDA
approved)
#LCSM
1
27
68
A great pleasure to share our last manuscript “Treatment-driven tumour
#heterogeneity
and drug
#resistance
: lessons from solid
#tumours
”
** Improving the understanding of
#cancer
heterogeneity is the key to improve the treatment performance
Find it here
0
21
68
🔥🆕
@Nature
resistance to KRAS(G12C) inhibition - a must-read!
A subset of pts acquired KRAS,NRAS or BRAF muts; & resistance in this setting may be delayed by co-targeting of ERK signalling intermediates…
@kRasKickers
#LCSM
0
30
69
🚨💡
@myESMO
#Virtual
Plenary
Excellent comprehensive table by Natasha Leighl (to keep) reporting different immuno-based first-line options for met+ NSCLC with focus on the related impact on survival, tox, QoL, PDL1, TMB, smoking history & genomics data
#LCSM
#LungCancer
👇👇👇
0
19
69
🆕in
@CCR_AACR
an analysis investigating the efficacy of Osi in pts with lung cancer harbouring *uncommon* EGFR exon 19 del mut’s
E746_A750del was associated with significantly prolonged mPFS with 1L Osi vs. L747_A750>P (21.3 vs. 11.7m; [HR] 0.52 ; p=0.043).
Understanding
3
21
70
Testing for
#COVID19
in
#lungcancer
patients
#LCSM
#OncoAlert
Just out our editorial in
@Annals_Oncology
@peters_solange
@TonyMok9
@t_mitsudomi
@AttiliMd
3
33
69
As usual, an amazing talk by
@UmbertoMalapel1
discussing the role of liquid biopsy and the integration with tissue, for a better characterisation and understanding of lung cancer heterogeneity! Bravo 👏🙌!!
#WCLC23
@IASLC
#LCSM
1
17
69
🚨
#ESMO20
#LCSM
KEYNOTE-024 5-yr OS update: 1L pembro vs p-chemo in pts w/ mNSCLC and PD-L1 ≥50% by J.R. Brahmer
@HopkinsThoracic
▪️39 pts completed 35 cycles (25.32%) (retreat 12pts)
▪️mOS 26.3 vs 13.4% (HR = 0.62)
▪️5yrs-OS rate: 31.9 vs 16.3%
👉That’s it! What else?!
3
29
69
🆕 in
@Annals_Oncology
an interesting Industry Corner Perspectives discussing “Paradigms for the development of transformative medicines - lessons from the
#EGFR
story” by W.Pao & Y.A. Nagel
@Roche
#LCSM
Highly recommended to read!
2
25
65
#ASCO21
#LCSM
🎯Keypoint slides from Day-1 metastatic session discussing two investigational agnostic treatment (no-biomarker driven) to overcome acquired resistance in EGFR-mutant
#lungcancer
-
#Amivantamab
plus
#Lazertinib
-
#Patritumab
deruxtecan (HER3-DXd)
@EGFRResisters
0
32
66
🛎 📣simply, an amazing read just published on
@NatureRevCancer
@jrm_black
&
@NickyMcGranahan
reviewed the intra-tumour heterogeneity & the clonal selection within the
#cancer
genome and beyond in
#tumour
evolution, to improve outcome for
#patients
#MedEd
#LCSM
#BCSM
0
15
67
Ready for the
#ELCC19
Here the best
@myESMO
@IASLC
selected abst for oral presentation, with my comments!
1️⃣CM451 of Nivo +/- Ipi as maintenance in SCLC
2️⃣MYSTIC analysis by clinical char’tcs
3️⃣KN24 final analysis
4️⃣Elderly pooled analysis from KN010 /024/042
#LCSM
#OncoAlert
1
29
67
💡Just out
@myESMO
Malignant pleural
#mesothelioma
Clinical Practice Guidelines for diagnosis, treatment & follow-up
@Annals_Oncology
#LCSM
An essential read for all the community! Congrats to all the authors & ESMO Guidelines Committee
1
27
65
🚨🆕Just out on
@TheLancetOncol
the TERAVOLT study, evaluating the impact of
#COVID19
in pts w/ thoracic cancers
#LCSM
👉🏻Our data suggest high mortality (33%) & low admission to ICU (10%) in pts w/ thoracic
#cancer
Thanks
@marinagarassino
&
@peters_solange
0
27
63
#ESMO21
#LCSM
Therapeutic approaches in HER2 mutant NSCLC
Excellent summary tables by
@danieltanmd
⚠️Limited results to move these drugs in first-line setting
2
27
63
0
19
65